Cellectar Biosciences Inc (STU:NV4)
€ 0.6 -0.58 (-49.15%) Market Cap: 50.05 Mil Enterprise Value: 30.97 Mil PE Ratio: 0 PB Ratio: 17.13 GF Score: 38/100

Cellectar Biosciences Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript

Jul 14, 2021 / 07:00PM GMT
Release Date Price: €8.9 (-2.20%)
Ahu Demir
Ladenburg Thalmann & Co. Inc. - Analyst

(Audio in progress) Cellectar Biosciences presentation. From the Company, we have the CEO and the President, James Caruso. Jim, thank you so much for joining us today. Really appreciate your time. I will turn it over to you for your presentation. If time allows, I'll ask a couple of questions, and you can take it over for your presentation. Thank you.

James Caruso
Cellectar Biosciences, Inc. - President, CEO & Director

All right, terrific. Thank you, Dr. Demir, and certainly good afternoon to all. I thank you for your interest in Cellectar Biosciences and obviously your participation in this presentation. Cellectar is traded on the Nasdaq exchange under the ticker symbol CLRB. Here you can see the obligatory Safe Harbor statement. Of course, I also direct you to our SEC filings.

On slide 3, you can view the presentation topics. Today I will provide a general overview with a focus on our lead asset, which is CLR 131 for adult hematology indications.

Slide 4 is our company overview.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot